GO
| HSI1 | 24,175.12 | +144.94 | 339.59B |
| HSCEI1 | 8,039.19 | +41.90 | 95.13B |
| Back Zoom + Zoom - Block Traded | |
|
SBP GROUP (01177.HK) Receives NMPA Acceptance for New Drug Marketing Application of TQB3454 Tablets
2026-07-10 17:20:33 SBP GROUP (01177.HK) announced that TQB3454 tablets, an "IDH1 inhibitor" independently developed by Chia Tai Tianqing Pharmaceutical, a subsidiary of the group and classified as a national Class 1 innovative drug, have submitted a new drug marketing application to the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China and received acceptance for the treatment of advanced biliary tract cancer (BTC) with IDH1 mutations. AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |